We had the privilege of sitting down with Angelica Loskog, Professor of Immunotherapy at Uppsala University in Sweden and the CEO of Lokon Pharma, a cutting-edge immunotherapy company making strides in the field. As a leader in the realm of oncolytic viruses and immunostimulatory gene therapy, Professor Loskog shared valuable insights into Lokon Pharma’s groundbreaking work.
RELATED:
- Positive Phase I Data from Oncolytic Virotherapy Trial
- Oncolytic Virus Immunotherapy: A Revolutionary Approach in Immuno-Oncology
- William Coley, the Father of Cancer Immunotherapy and His Legacy
Want to read more about new advances in immuno-oncology and ongoing immune therapies? Sign up to our Immuno newsletter to receive leading experts opinions, research and cutting-edge presentations on the latest advancements in cancer immunotherapy, with dedicated sessions on different therapeutic modalities as well as case studies on innovative preclinical and translational tools.
